Watch Fireside Chat Below, or Click HERE: IPO Edge hosted a fireside chat with West Point Gold Corp. (TSX: WPG) (OTC: WPGCF) Chief Executive Officer Derek Macpherson, moderated by IPO Edge Editor-in-Chief John Jannarone and Editor-at-Large Jarrett Banks in a video session...

Watch Video Highlights Below, or Click HERE:  Tech Edge hosted a fireside chat on June 9 at Pax8 Beyond 2026 in Salt Lake City with Chance Weaver, Vice President of AI Adoption at Pax8. The in-person interview was joined by Editor-in-Chief...

By Karen Roman Fortitude Mining Holdings, Inc., a Zcash mining platform, has agreed to merge with HeartSciences Inc. (Nasdaq: HSCS) in an all-stock transaction that will take the company public. The combined company is expected to trade on the Nasdaq under...

Watch Video Highlights Below, or Click HERE:  Tech Edge hosted a fireside chat on June 9 at Pax8 Beyond 2026 in Salt Lake City with Libby McIlhany, Chief Product Officer and Craig Donovan,  Chief Operating Officer, at Pax8. The in-person interview was joined by Editor-in-Chief...

Watch Video Highlights Below, or Click HERE:  Tech Edge hosted a fireside chat on June 7 at Pax8 Beyond 2026 in Salt Lake City with Nick Heddy, President and Chief Commerce Officer at Pax8. The in-person interview was joined by Editor-in-Chief...

Download the Complete Report Here Local Bounti Corporation (LOCL) From Capacity Ramp to Yield-Led Growth: Stack & Flow, Retail Demand, and SKU Breadth Support LOCL’s Next Phase LOCL is a branded CEA fresh-produce platform built around patented Stack & Flow...

Local Bounti Corporation (LOCL) From Capacity Ramp to Yield-Led Growth: Stack & Flow, Retail Demand, and SKU Breadth Support LOCL’s Next Phase Subscribe to our Weekly Newsletter to Receive All Research Contact: Executives-Edge.com karenr@capmarketsmedia.com 

By Karen Roman Prolium Bioscience, Inc. said it dosed its first patient in Phase 1/2 study of PRO-203, a T-cell engager treatment for systemic sclerosis, following the completion of a study in 20 healthy volunteers. The company also completed the...

By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) reported in vitro proof-of-concept data validating its BiTAC-ADC platform for cancer therapies, with selective tumor cell killing while sparing healthy cells. The company will showcase partnering opportunities for its platform at the...